San Diego-based Trovagene Inc., a molecular diagnostics company, announced that it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech Republic.

The collaboration will use Trovagene’s precision cancer monitoring technology in two clinical studies to detect early mutations that indicate resistance to targeted therapies to treat colorectal and lung cancer.

"Genomac is an important clinical study partner of Trovagene, and we are impressed with the Institute's cancer genomic program," said Mark Erlander, chief scientific officer of Trovagene. "Our initial work examining KRAS mutations in archived samples are encouraging. We are increasing the size and scope of this clinical program to demonstrate the utility of our novel molecular diagnostic platform and its potential to improve the standard of care for cancer patients."